| NCT01259219 | Children With Confirmed HIV Infection|Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose|Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment | Drug: Mycobutin | Harriet Shezi Children's Clinic | Phase 1 | 2010-11-01 | 2010-12-13 |
| NCT01663168 | HIV|Tuberculosis | Drug: Rifabutin | Justine Boles|Abbott|Medical Research Council | Phase 2 | 2011-12-01 | 2012-08-08 |
| NCT00810446 | Non-tuberculous Mycobacterial Diseases (Including MAC Disease)|Tuberculosis|Inhibition of Disseminated Mycobacterium Avium Complex (MAC) Disease Associated With HIV Infections | Drug: rifabutin | Pfizer | | 2009-06-01 | 2017-03-06 |
| NCT00810407 | Tuberculosis|Non-tuberculous Mycobacterial Diseases (Including MAC Disease) | Drug: rifabutin | Pfizer | | 2008-11-01 | 2016-09-20 |
| NCT02415985 | HIV|Tuberculosis | Drug: Lopinavir/r will be supplied by NHSO/GPO|Drug: Rifabutin | The HIV Netherlands Australia Thailand Research Collaboration|Bamrasnaradura Infectious Diseases Institute|Chulalongkorn University | Phase 2 | 2015-06-01 | 2017-02-22 |
| NCT00651066 | HIV Infections|Tuberculosis | Drug: rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1|Drug: rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2 | French National Agency for Research on AIDS and Viral Hepatitis|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | Phase 2 | 2010-06-01 | 2013-07-16 |
| NCT01341184 | Tuberculosis | Drug: Rifabutin|Drug: Rifampin|Drug: TMC207 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | 2011-10-01 | 2013-04-25 |
| NCT01894776 | HIV Infection|HIV-1 Infection|Mycobacterium Avium Complex (MAC) | Drug: Rifabutin|Drug: Maraviroc | Ottawa Hospital Research Institute|Pfizer | Phase 1 | 2013-06-01 | 2015-03-02 |
| NCT00640887 | HIV Infections|Tuberculosis | Drug: rifabutin in combination with efavirenz|Drug: rifabutin in combination with nevirapine|Drug: rifabutin in combination with lopinavir/ritonavir | French National Agency for Research on AIDS and Viral Hepatitis | Phase 2 | 2009-02-01 | 2011-06-17 |
| NCT01615614 | Healthy | Drug: Rilpivirine|Drug: Rifabutin | Janssen R&D Ireland | Phase 1 | 2012-04-01 | 2014-03-27 |
| NCT00869518 | Staphylococcus Aureus|HIV Infections | Drug: rifabutin plus trimethoprim sulfamethoxazole|Drug: placebo plus trimethoprim-sulfamethoxazole | University of California, San Francisco | Phase 2 | 2009-07-01 | 2014-04-23 |
| NCT00598897 | Mycobacterium Avium Complex Lung Disease | Drug: clarithromycin, rifabutin | The University of Texas Health Science Center at Tyler|Abbott|Pfizer | Phase 4 | 1995-08-01 | 2008-01-11 |
| NCT02251171 | Healthy | Drug: Tipranavir|Drug: Ritonavir|Drug: Rifabutin | Boehringer Ingelheim | Phase 1 | 2003-08-01 | 2014-09-25 |
| NCT00925535 | Healthy Volunteers | Drug: Lersivirine|Drug: Rifabutin|Drug: Lersivirine|Drug: Rifabutin | Pfizer | Phase 1 | 2010-05-01 | 2010-09-17 |
| NCT00023400 | HIV Infections|Tuberculosis | Drug: Nelfinavir|Drug: Rifabutin | Centers for Disease Control and Prevention|VA Office of Research and Development | Phase 4 | 2000-02-01 | 2005-09-01 |
| NCT00023413 | HIV Infections|Tuberculosis | Drug: Rifabutin|Drug: Efavirenz | Centers for Disease Control and Prevention|VA Office of Research and Development | Phase 2 | 1999-11-01 | 2012-06-04 |
| NCT00023348 | HIV Infections|Tuberculosis | Drug: Isoniazid|Drug: Rifabutin | Centers for Disease Control and Prevention|VA Office of Research and Development | Phase 2|Phase 3 | 1999-07-01 | 2005-09-09 |
| NCT01231542 | Infection, Human Immunodeficiency Virus | Drug: GSK1349572|Drug: Rifampin|Drug: Rifabutin | ViiV Healthcare|Shionogi|GlaxoSmithKline | Phase 1 | 2011-05-01 | 2011-12-21 |
| NCT00598962 | Mycobacterium Avium Complex | Drug: Azithromycin, Rifabutin | The University of Texas Health Science Center at Tyler|Pfizer | Phase 4 | 1994-12-01 | 2008-01-11 |
| NCT00743470 | HIV|Tuberculosis | Drug: lopinavir/ritonavir|Drug: rifabutin | Abbott | Phase 1 | 2008-08-01 | 2010-10-29 |
| NCT02138084 | HIV/AIDS | Drug: BMS-663068|Drug: Rifabutin|Drug: Ritonavir | Bristol-Myers Squibb | Phase 1 | 2014-05-01 | 2014-09-10 |
